-
Phase 3
-
-
18+Age Range
-
91Locations
-
Recruiting
Recruiting
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Active Comparator: Kd (Carfilzomib + Dexamethasone)
Experimental: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)